DSP 7888

Drug Profile

DSP 7888

Alternative Names: DSP-7888

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Class Antineoplastics; Peptide vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioma; Myelodysplastic syndromes
  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 23 Feb 2017 Kyoto Prefectural University of Medicine plans a phase II trial for Soft tissue sarcoma (In adolescent, In adult, In child, In infant, In neonate) in Japan (JMA-IIA00276)
  • 03 Dec 2016 Preliminary efficacy and adverse events data from a phase I/II trial in Myelodysplastic syndrome presented at American Society of Hematology Annual Meeting and Exposition (ASH-2016)
  • 04 Nov 2016 Phase-II clinical trials in Glioma (In adolescents, In children, In infants, In neonates, Late-stage disease, Recurrent, Second-line therapy or greater) in Japan (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top